Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:29:45 05/06/2024 am IST			5-day change	1st Jan Change
7.2 ^USD	+2.86%		-9.26%	-8.63%

28/05	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
28/05	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024

May 16, 2024 at 02:46 am IST

Outlook Therapeutics, Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported net loss was USD 114.29 million compared to USD 6.65 million a year ago. Basic loss per share from continuing operations was USD 8.01 compared to USD 0.52 a year ago.
For the six months, net loss was USD 125.47 million compared to USD 25.32 million a year ago. Basic loss per share from continuing operations was USD 9.2 compared to USD 2.09 a year ago.

Latest news about Outlook Therapeutics, Inc.

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	28/05	MT
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	28/05	CI
CoStar Group has room for expansion	21/05
Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024	16/05
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05	CI
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	13/05	MT
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	13/05	CI
Outlook Therapeutics, Inc. Announces Change in Headquarters Address	01/05	CI
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04	CI
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04	CI
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
Outlook Therapeutics Shares Rise After BTIG Upgrade	28/03	MT
BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	27/03	MT
Outlook Therapeutics Reports Secondary Share Offering	26/03	MT
Sector Update: Health Care Stocks Ease Late Afternoon	23/03	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	22/03	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22/03	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	22/03	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03	CI
Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors	18/03	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	13/03	MT
North American Morning Briefing : S&P 500 Seen -2-	16/02	DJ
Outlook Therapeutics Shares Climb Following Upgrade by Chardan	16/02	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	15/02	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	15/02	MT

Chart Outlook Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.19 USD

Average target price

38.43 USD

Spread / Average Target

+434.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OUTLOOK THERAPEUTICS, INC.	-8.63%	168M
MODERNA, INC.	+46.19%	55.7B
IQVIA HOLDINGS INC.	-6.14%	39.57B
LONZA GROUP AG	+39.19%	39.91B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	18.94B
BIO-TECHNE CORPORATION	-0.35%	12.12B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.12B
MEDPACE HOLDINGS, INC.	+28.38%	12.17B

Other Biotechnology & Medical Research